Gender disparities in Parkinson’s disease

Parkinson’s disease is a chronic neurodegenerative disorder of unknown etiology. Therearesparse data on gender differences in this disorder, but it is clear that there are gender discrepancies in incidence, symptoms, medication effects and treatments. There also appear to be lifecycle fluctuations in the disease course of female Parkinson’s disease patients. The effect of estrogen in this disorder is multifold and its role in the development and treatment of PD will be discussed.

[1]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[2]  Bastiaan R Bloem,et al.  Gender differences in Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  E. Schechtman,et al.  Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. , 2002, Neurology.

[4]  S. Cummings,et al.  Is Postmenopausal Estrogen Therapy Associated With Neuromuscular Function or Falling in Elderly Women , 1995 .

[5]  J. Cummings,et al.  Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. , 2002, Archives of neurology.

[6]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[7]  S. Lo,et al.  Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations , 2000, Neurology.

[8]  H. Engler,et al.  Gender differences in Parkinson's disease symptom profile , 2000, Acta neurologica Scandinavica.

[9]  L. Shulman,et al.  Gender differences in Parkinson's disease. , 2007, Gender medicine.

[10]  T. L. Thompson,et al.  Estrogen mediated inhibition of dopamine transport in the striatum: Regulation by Gαi/o , 2005 .

[11]  C. Wielinski,et al.  Frequency, Reasons, and Risk Factors of Entacapone Discontinuation in Parkinson Disease , 2004, Clinical neuropharmacology.

[12]  C. Marsden,et al.  Menstrual‐related fluctuations in Parkinson's disease , 1986, Movement disorders : official journal of the Movement Disorder Society.

[13]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[14]  A H V Schapira,et al.  Present and future drug treatment for Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  M. Contin,et al.  Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? , 2003, Neurological Sciences.

[16]  C. Markham,et al.  An examination of male‐female differences in progression and mortality of Parkinson's disease , 1990, Neurology.

[17]  E. Barrett-Connor,et al.  Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. , 2002, The American journal of medicine.

[18]  Isolated hand palsy due to cortical infarction: Localization of the motor hand area , 2002, Neurology.

[19]  R. Weinshilboum,et al.  Human liver catechol‐O‐methyltransferase pharmacogenetics , 1990, Clinical pharmacology and therapeutics.

[20]  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.

[21]  S. Ho,et al.  Human catechol-O-methyltransferase down-regulation by estradiol , 2003, Neuropharmacology.

[22]  M. Horstink,et al.  Effects of female sex steroids on Parkinson's disease in postmenopausal women. , 1999, Clinical neuropharmacology.

[23]  G. Hariz,et al.  Gender distribution in surgery for Parkinson's disease. , 2000, Parkinsonism & related disorders.

[24]  T. L. Thompson,et al.  Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o. , 2005, European journal of pharmacology.

[25]  B. Schoenberg,et al.  A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. , 1985, Archives of neurology.

[26]  W. Weiner,et al.  The effect of pregnancy in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[27]  M. Hariz,et al.  Gender differences in disability and health‐related quality of life in patients with Parkinson's disease treated with stereotactic surgery , 2003, Acta neurologica Scandinavica.

[28]  P. Aridon,et al.  Risk of Parkinson disease in women , 2004, Neurology.

[29]  S. Ho,et al.  Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. , 1999, Molecular pharmacology.

[30]  V. Ravindranath,et al.  Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  S. Fahn,et al.  The effect of estrogen replacement on early Parkinson’s disease , 1999, Neurology.

[32]  F. Speizer,et al.  Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease , 2003, Neurology.

[33]  F. Holsboer,et al.  Neuroprotection against oxidative stress by estrogens: structure-activity relationship. , 1997, Molecular pharmacology.

[34]  V Kaasinen,et al.  Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. , 2001, Brain : a journal of neurology.

[35]  P. Bédard,et al.  Oestrogens and extrapyramidal system. , 1977, Lancet.

[36]  K. Marder,et al.  A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. , 1992, Archives of neurology.

[37]  C. Wright,et al.  Steady‐State Pharmacokinetic Properties of Pramipexole in Healthy Volunteers , 1997, Journal of clinical pharmacology.

[38]  V. Ravindranath,et al.  Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP‐mediated neurodegeneration , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  G. C. Wagner,et al.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. , 2003, Journal of pharmacological sciences.

[40]  G. Wooten,et al.  Are men at greater risk for Parkinson’s disease than women? , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  J. Langston,et al.  MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. , 1984, Acta neurologica Scandinavica. Supplementum.

[42]  J. Growdon,et al.  Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients , 1998, Neurology.

[43]  O. Suchowersky.  Parkinson’s disease: Medical treatment of moderate to advanced disease , 2002, Current neurology and neuroscience reports.

[44]  A. E. Lang,et al.  Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review , 2002, Neurology.

[45]  C. Beyer,et al.  Estrogen: A multifunctional messenger to nigrostriatal dopaminergic neurons , 2000, Journal of neurocytology.

[46]  K. Lapane,et al.  Estrogen use among nursing home residents with a diagnosis of Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[47]  C. Tanner,et al.  Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease , 2005, Neurology.

[48]  D. Dluzen,et al.  Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system , 2001, Neuroscience.

[49]  Nir Giladi,et al.  Hormones and Parkinson's disease , 1995, Neurology.

[50]  D. Dluzen,et al.  Inhibition of striatal dopamine transporter activity by 17beta-estradiol. , 1998, European journal of pharmacology.

[51]  H. Larsen,et al.  Better postural balance in elderly women receiving estrogens. , 1997, American journal of obstetrics and gynecology.

[52]  S. Ho,et al.  Epidemiologic study of Parkinson's disease in Hong Kong , 1989, Neurology.

[53]  G. Naglie,et al.  Survival in Parkinson disease , 2005, Neurology.

[54]  S. Leurgans,et al.  Menstrual-related changes in motoric function in women with Parkinson’s disease , 2000, Neurology.

[55]  P. Blanchet,et al.  Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients , 1999, Neurology.

[56]  D. Dorsa,et al.  Modulation of Bcl‐2 expression: a potential component of estrogen protection in NT2 neurons , 1998, Neuroreport.

[57]  M. Mattson,et al.  Estrogens Attenuate and Corticosterone Exacerbates Excitotoxicity, Oxidative Injury, and Amyloid β‐Peptide Toxicity in Hippocampal Neurons , 1996, Journal of neurochemistry.

[58]  Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women. The Women???s Health Initiative Memory Study: A Randomized, Controlled Trial , 2003 .

[59]  D. Dluzen,et al.  Developmental and Genetic Influences upon Gender Differences in Methamphetamine‐Induced Nigrostriatal Dopaminergic Neurotoxicity , 2004, Annals of the New York Academy of Sciences.

[60]  K. Marder,et al.  Postmenopausal estrogen use and Parkinson's disease with and without dementia , 1998, Neurology.

[61]  W. Koller,et al.  Estrogen treatment of dyskinetic disorders , 1982, Neurology.

[62]  M. Thun,et al.  Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. , 2004, American journal of epidemiology.

[63]  D. Rubinow,et al.  Estrogen replacement in perimenopause-related depression: a preliminary report. , 2000, American journal of obstetrics and gynecology.

[64]  R. Greene,et al.  The role of reproductive hormones in maintaining cognition. , 2002, Obstetrics and gynecology clinics of North America.

[65]  G. Wooten,et al.  Postmenopausal estrogen use affects risk for Parkinson disease. , 2004, Archives of neurology.

[66]  J. O'Callaghan,et al.  The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity , 1998, Annals of the New York Academy of Sciences.

[67]  E. Bézard,et al.  Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment , 2004, Neurology.

[68]  R. Saunders-Pullman.  Estrogens and parkinson disease , 2003, Endocrine.

[69]  A. Ascherio,et al.  Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease , 2006, The Journal of Neuroscience.

[70]  Feucia Hupperx.  Cognition and Dementia , 2004, Obstetrics and gynecology.

[71]  J. Ahlskog.  Movement Disorders: A Comprehensive Survey , 1989 .

[72]  D. Dluzen,et al.  Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats , 2000, Brain Research.

[73]  D. Schaid,et al.  Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case‐control study , 2001, Movement disorders : official journal of the Movement Disorder Society.

[74]  M. Horstink,et al.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system , 2003, Endocrine.

[75]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[76]  L. Shulman.  Is there a connection between estrogen and Parkinson's disease? , 2002, Parkinsonism & related disorders.

[77]  M. Panisset,et al.  Salivary production in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[78]  P. Wise.  Estrogens and neuroprotection , 2002, Trends in Endocrinology & Metabolism.

[79]  D. Dorsa,et al.  The Mitogen-Activated Protein Kinase Pathway Mediates Estrogen Neuroprotection after Glutamate Toxicity in Primary Cortical Neurons , 1999, The Journal of Neuroscience.

[80]  W. M. Chase,et al.  Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics , 2002, Neurology.

[81]  P. Bédard,et al.  ŒSTROGENS AND EXTRAPYRAMIDAL SYSTEM , 1977, The Lancet.

[82]  M. Horstink,et al.  Estrogen and Parkinson's disease. , 2003, Advances in neurology.

[83]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[84]  A. Quattrone,et al.  Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. , 2005, Archives of neurology.

[85]  A. Quattrone,et al.  Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease , 2002, Clinical neuropharmacology.

[86]  I. Wiklund,et al.  Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. , 1993, American journal of obstetrics and gynecology.